Lysergide d-tartrate: Difference between revisions

Lysergide d-tartrate
Identifiers
	IUPAC name (6aR,9R)-N,N-diethyl-7-methyl-6,6a,8,9-tetrahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide;(2S,3S)-2,3-dihydroxybutanedioic acid;
CAS Number	32426-57-6;
ChemSpider	180710;
UNII	7WNP51KA7M;
Chemical and physical data
Formula	C24H31N3O7
Molar mass	473.526 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN1[C@]2(C(C=3C=4C(C2)=CNC4C=CC3)=C[C@@H](C(N(CC)CC)=O)C1)[H].[C@H]([C@@H](C(O)=O)O)(C(O)=O)O;
	InChI InChI=InChI=1S/C20H25N3O.C4H6O6/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14;5-1(3(7)8)2(6)4(9)10/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3;1-2,5-6H,(H,7,8)(H,9,10)/t14-,18-;1-,2-/m10/s1; Key:HQMPRARIZOUKRO-JDQBHMBOSA-N;

Browse history interactively

← Previous edit Next edit →

Content deleted Content added

VisualWikitext

Inline

Revision as of 15:16, 19 May 2024

Lysergide d-tartrate ((LSD, d-LSD, LSD-25''') is an actuall d-LSD-25 that was discovered by Albert Hoffman in 1938 by pharmacutical company Sandoz. Even though it is a drug that is already one of the most researched one if not the most those scientific papers were ignored and was made illegal 1971 due to poor discipline and misuse of people publicly. Its a chemical that helped scientist not only treat disorders and addiction but is also the reason we unserstand basic pharmacokinetics of drus on the brain. After 1971 everything went to a halt and missinformation was spread about this medicine Now after 53 years company MindMed has named it MM-120 for the porpuse of securing a patent for it. Now it was finally granted as a [["breakthrough" therapy|therapy]] status for the treatment of [[Generalized Anxiety Disorder]] by the [[FDA]] in March 2024, after finally realising antidepresants don't treat anything, only preventing symptoms during their course of their action. even though such discoveries and many more about lsd were already known and researched from 1947s and to 1965s when Sanoz stopped destribution of LSD-25 to clinics (A. Hoffman- LSD My ProblemChild,)

References

@@ Line 43: / Line 43: @@
 }}
+'''Lysergide d-tartrate''' ((LSD, d-LSD, LSD-25<nowiki>'''</nowiki>) is an actuall d-LSD-25 that was discovered by Albert Hoffman in 1938 by pharmacutical company Sandoz. Even though it is a drug that is already one of the most researched one if not the most those scientific papers were ignored and was made illegal 1971 due to poor discipline and misuse of people publicly. Its a chemical that helped scientist not only treat disorders and addiction but is also the reason we unserstand basic pharmacokinetics of drus on the brain. After 1971 everything went to a halt and missinformation was spread about this medicine  Now after 53 years company MindMed has named it MM-120 for the porpuse of <ins>securing</ins> a patent <ins>for</ins> it. <ins>Now</ins> it was finally granted as a <nowiki>[["breakthrough" therapy|therapy]]</nowiki> status for the treatment of <nowiki>[[Generalized Anxiety Disorder]]</nowiki> by the <nowiki>[[FDA]]</nowiki> in March 2024,<ins> after finally realising antidepresants don't treat anything, only preventing symptoms during their course of their action. </ins>even though such discoveries and many more about lsd were already known and researched from 1947s and to 1965s when Sanoz stopped destribution of LSD-25 to clinics (A. Hoffman- LSD My ProblemChild,)
-'''Lysergide d-tartrate''' ('''MM120''') is an [[investigational new drug]] that was granted [[breakthrough therapy]] status for the treatment of [[Generalized Anxiety Disorder]] by the [[FDA]] in March 2024.<ref name="drugtopics">{{cite web | vauthors = Meara K |title=FDA Grants Breakthrough Therapy Designation to LSD-Based Treatment for Generalized Anxiety Disorder |url=https://www.drugtopics.com/view/fda-grants-breakthrough-therapy-designation-to-lsd-based-treatment-for-generalized-anxiety-disorder |website=Drug Topics |access-date=8 March 2024 |language=en |date=7 March 2024}}</ref> It is a [[Salt (chemistry)|salt]] of [[lysergide]].<ref>{{cite news | vauthors = Grinstein JD |title=Licit Activity: MindMed Collaborators Announce Positive Phase II Results for LSD in Major Depressive Disorder |url=https://www.genengnews.com/gen-edge/licit-activity-mindmed-collaborators-announce-positive-phase-2-results-for-lsd-in-major-depressive-disorder/ |access-date=8 March 2024 |work=GEN - Genetic Engineering and Biotechnology News |date=14 April 2023}}</ref><ref name="cnn">{{cite news | vauthors = LaMotte S |title=Single dose of LSD provides immediate, lasting anxiety relief, study says |url=https://www.cnn.com/2024/03/07/health/lsd-anxiety-fda-breakthrough-therapy-wellness/index.html |access-date=8 March 2024 |work=CNN |date=7 March 2024 |language=en}}</ref>
 ==References==